All News
Filter News
Found 808,644 articles
-
Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval
12/13/2023
Medivir AB announced that it has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug substance for the planned phase 2b to enable study drug availability end of 2024 and ensure maximum momentum in the fostrox development program.
-
Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups
12/13/2023
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.
-
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition
12/13/2023
BioVaxys Technology Corp. announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical development stage assets in oncology and other immunological fields formerly owned by an unnamed biotechnology company and now held by the secured creditor.
-
EVerZom: Therapeutic Ambition in Exosome Biotherapies
12/13/2023
EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.
-
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
12/13/2023
Pharming Group N.V. announces the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies beyond activated phosphoinositide 3-kinase delta syndrome.
-
Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders
12/13/2023
Encellin announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
-
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
12/13/2023
Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.
-
iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506
12/13/2023
iECURE, Inc. announced today that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506 (formerly GTP-506), an investigational therapy in development for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.
-
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
12/13/2023
Dizal announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer patients with EGFR exon 20 insertion mutations were published in the peer-reviewed journal The Lancet Respiratory Medicine.
-
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
12/13/2023
Transcenta Holding Limited announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging.
-
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
12/13/2023
Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.
-
University Hospital Birmingham Improves Craniomaxillofacial Tumor Surgery Using 3D Printed Tailored Surgical Guides
12/13/2023
Stratasys Ltd. (Nasdaq: SSYS) (“Stratasys” or the “Company”), a leader in polymer 3D printing solutions, has shared that the University Hospital Birmingham in England is delivering improved outcomes for head and neck cancer patients.
-
Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries
12/13/2023
Vergent Bioscience announced that the company has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung.
-
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04
12/13/2023
Levicept Ltd announces it has completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent.
-
LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
12/13/2023
BioArctic AB's partner Eisai announced that LEQEMBI will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance drug price list.
-
AltPep Appoints Soon Hyouk Lee to Newly Created Position of Chief Business Officer
12/13/2023
AltPep Corporation today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep.
-
BioLabs and Promega Announce Collaboration to Support Young Biotech Companies
12/13/2023
BioLabs and Promega announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.
-
New Horizons for CellCore Biosciences: Jen Kelly of Fullscript Joins as Vice President of Business Development
12/13/2023
CellCore Biosciences has excitedly announced Jen Kelly as their Vice President of Business Development.
-
Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders
12/13/2023
Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.
-
SonALAsense Presents Preliminary Data From Clinical Study in Patients With Deadly Pediatric Brain Tumor
12/13/2023
SonALAsense today announced the presentation of positive preliminary data from the ongoing Phase 1/2 SDT-201 study in Diffuse Intrinsic Pontine Glioma (DIPG).